• About us
• Contact

Advertisement

Organisation › Details

ObsEva (Group)

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the Nasdaq Capital Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. *

 

	Start	2012-01-01 established
	Today	ObsEva S.A. (SIX: OBSN)
	Industry	nolasiban (OBE001)
	Industry 2	reproductive health
	Person	Loumaye, Ernest (ObsEva 201211– CEO + Co-founder before PregLem SA CEO + founder + Ipsen + Serono)
	Person 2	Adams, Timothy M. (Tim) (ObsEva 201701– CFO located in US before Demandware + athenahealth + Cytyc)
	Region	Plan-les-Ouates GE
	Country	Switzerland
	Street	12 Chemin des Aulx
	City	1228 Plan-les-Ouates GE
	Tel	+41-22-552-3840
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: ObsEva S.A.. (2/24/23). "Press Release: ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland". Geneva.
		Record changed: 2023-04-15

Advertisement

More documents for ObsEva (Group)

• [1] ObsEva S.A.. (2/24/23). "Press Release: ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland". Geneva....
• [2] ObsEva S.A.. (11/22/22). "Press Release: ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million". Geneva....
• [3] ObsEva S.A.. (10/26/22). "Press Release: ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings". Geneva....
• [4] ObsEva S.A.. (12/9/19). "Press Release: ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix". Geneva & Boston, MA....
• [5] ObsEva S.A.. (1/25/17). "Press Release: ObsEva SA Announces Pricing of Initial Public Offering". Geneva....
• [6] ObsEva S.A.. (1/17/17). "Press Release: ObsEva Expands Leadership Team and Board of Directors with Industry Veterans". Geneva....
• [7] ObsEva S.A.. (1/13/17). "Press Release: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor". Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.